MERECA Study Reveals Survival Benefits for Metastatic Synchronous mRCC with Combo of Ilixadencel plus Sutent TrialSite News, 10 Feb 2020 The combination of ilixadencel plus sunitinib (Sutent) has evidenced favorable survival compared with sunitinib alone in…